These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1398521)

  • 21. Adenocarcinoma of the prostate with endometrioid features. A light microscopic and immunohistochemical study of ten cases.
    Epstein JI; Woodruff JM
    Cancer; 1986 Jan; 57(1):111-9. PubMed ID: 2416422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The natural course of low grade, non-metastatic prostatic carcinoma.
    Adolfsson J; Rönström L; Carstensen J; Löwhagen T; Hedlund PO
    Br J Urol; 1990 Jun; 65(6):611-4. PubMed ID: 2372673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sarcomatoid carcinoma of the prostate: a study of 42 cases.
    Hansel DE; Epstein JI
    Am J Surg Pathol; 2006 Oct; 30(10):1316-21. PubMed ID: 17001164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate specific antigen and prostatic acid phosphatase immunoreactivity as prognostic indicators of advanced prostatic carcinoma.
    Sakai H; Yogi Y; Minami Y; Yushita Y; Kanetake H; Saito Y
    J Urol; 1993 May; 149(5):1020-3. PubMed ID: 7683340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histological determinants of the vascular surface in prostatic carcinoma.
    Barth PJ; Ghafouri-Sanati H; Köhler HH; Bittinger A; Riedmiller H
    Urol Res; 1997; 25(5):303-8. PubMed ID: 9373909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate.
    Abrahamsson PA; Wadström LB; Alumets J; Falkmer S; Grimelius L
    Pathol Res Pract; 1987 Jun; 182(3):298-307. PubMed ID: 2442732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
    Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
    Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
    Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
    Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression.
    van den Brûle FA; Waltregny D; Liu FT; Castronovo V
    Int J Cancer; 2000 Jul; 89(4):361-7. PubMed ID: 10956411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nuclear morphometry in automatic biopsy and radical prostatectomy specimens of prostatic carcinoma. A comparison.
    Mohler JL; Metts JC; Zhang XZ; Maygarden SJ
    Anal Quant Cytol Histol; 1994 Dec; 16(6):415-20. PubMed ID: 7710616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.
    Epstein JI; Amin MB; Reuter VE; Humphrey PA
    Am J Surg Pathol; 2017 Apr; 41(4):e1-e7. PubMed ID: 28177964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Argyrophilic prostatic carcinoma. Case report with literature review on prostatic carcinoid and "carcinoid-like" prostatic carcinoma.
    Almagro UA
    Cancer; 1985 Feb; 55(3):608-14. PubMed ID: 2578089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostatic adenocarcinoma with atrophic features: a study of 202 consecutive completely embedded radical prostatectomy specimens.
    Kaleem Z; Swanson PE; Vollmer RT; Humphrey PA
    Am J Clin Pathol; 1998 Jun; 109(6):695-703. PubMed ID: 9620026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urothelial carcinoma of the prostate.
    Goebbels R; Amberger L; Wernert N; Dhom G
    Appl Pathol; 1985; 3(4):242-54. PubMed ID: 3842265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostatic adenocarcinoma in colorectal biopsy: clinical and pathologic features.
    Lane Z; Epstein JI; Ayub S; Netto GJ
    Hum Pathol; 2008 Apr; 39(4):543-9. PubMed ID: 18234278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A theoretical rationale on the histogenesis of premalignant lesions and early carcinoma of the prostate.
    Botticelli AR
    Pathologica; 1994 Apr; 86(2):128-41. PubMed ID: 7524011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of pathological stage and clinical outcome in prostate cancer: an improved pre-operative model incorporating biopsy-determined intraductal carcinoma.
    Cohen RJ; Chan WC; Edgar SG; Robinson E; Dodd N; Hoscek S; Mundy IP
    Br J Urol; 1998 Mar; 81(3):413-8. PubMed ID: 9523662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroendocrine stains and proliferative indices of prostatic adenocarcinomas in transurethral resection samples.
    Speights VO; Cohen MK; Riggs MW; Coffield KS; Keegan G; Arber DA
    Br J Urol; 1997 Aug; 80(2):281-6. PubMed ID: 9284203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
    Borgmann V; al-Abadi H; Nagel R
    Am J Clin Oncol; 1988; 11 Suppl 1():S19-28. PubMed ID: 2968759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.